Bernard A. Fox: Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years
Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn:
“Best response rate for recurrent or metastatic Head and Neck Squamous Cell Carcinomas at AACR2024 was combination immunotherapy with UbiVac’s DPV-001 Dark Matter cancer vaccine/immunotherapy. I believe that the discovery of Cancer’s Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years and it has the potential to change how all cancers are treated.
DPV-001 is the first Dark Matter cancer vaccine given to patients and is an off-the-shelf immunotherapy designed to be a universal therapeutic vaccine for the majority of solid cancers. While we need to treat additional patients to confirm these promising results, we consider that DPV-001 is the only treatment containing cancer’s “Dark Matter” in a form that does not require HLA-matching, can stimulate broad immune reactivity, and we are actively investigating whether immunity to Dark Matter is responsible for the increased response rates in patients with cancer.
DPV-001 also contains 300+ shared cancer antigens and may be useful to boost TIL following adoptive immunotherapy. UbiVac is seeking funding for a series B round to expand operations, manufacture vaccine, and build a team to take DPV-001 to approval.”
Further Reading.
Source: Bernard A. Fox/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023